MedPath

Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia

Conditions
Heparin-Induced Thrombocytopenia
Thrombosis
Biomarkers
Interventions
Diagnostic Test: HIT with thrombosis
Registration Number
NCT03269019
Lead Sponsor
Wuhan Asia Heart Hospital
Brief Summary

Heparin induced thrombocytopenia (HIT) is a kind of catastrophic thrombotic complications after the application of heparin. If HIT without treatment, death rate is as high as 30% to 50%. Early diagnosis of HIT and prevention of thrombosis is very important.

This study is planned to assess the use of thrombotic biomarkers in patients with HIT, including thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy monitoring . These biomarkers are monitored in 5-14 days post-operation to assess the risk of thrombosis in HIT patients. All patients were followed up for 30 days, and clinical outcomes, including new thrombus and death, were recorded during follow-up.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Hospitalized patients undergoing cardiac surgery.
  • Receiving unfractionated heparin anticoagulation.
Exclusion Criteria
  • history of heparin-induced thrombocytopenia
  • pregnant woman

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
HIT-groupHIT with thrombosisThe patients with heparin-induced thrombocytopenia.
HITTs-groupHIT with thrombosisThe patients with heparin-induced thrombocytopenia with thrombosis.
Primary Outcome Measures
NameTimeMethod
Deaths30 days

All-cause deaths

Thrombotic event30 days

New thrombosis, including deep venous thrombosis,pulmonary embolism,Cerebral infarction,superior mesenteric artery embolism,artery embolism etc.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath